Showing results (211-220 of 219) with videos related to

Sort By:
Pageof 22
You have reached the last page of results.This site can display upto 219 results.
Pharmacogenomics|September 13, 2012
Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costsTalitha I Verhoef, William K Redekop, Rianne Mf van Schie, et al.
Pilot and Feasibility Studies|January 25, 2024
Supporting people with type 2 diabetes in effective use of their medicine through mobile health technology integrated with clinical care (SuMMiT-D pilot): results of a feasibility randomised trial, Andrew J Farmer, Julie Allen, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 24, 2021
Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa: An Open-Label, Randomized, Bayesian Noninferiority TrialPaul A Brogan, Barbara Arch, Helen Hickey, et al.
British Journal of Clinical Pharmacology|December 3, 2025
CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx)Cinzia Dello Russo, Iain Frater, Rebecca Kuruvilla, et al.
Pharmacogenomics|July 7, 2010
A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivativesTalitha I Verhoef, William K Redekop, Josep Darba, et al.
British Journal of Clinical Pharmacology|July 2, 2026
UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx)Dharmisha Chauhan, Cinzia Dello Russo, Jack Thompson, et al.
British Journal of Clinical Pharmacology|April 19, 2026
HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx)Lucy Galloway, Cinzia Dello Russo, Nicholas Bass, et al.
BMJ Open|May 9, 2025
Carboprost versus Oxytocin as the first-line treatment of primary postpartum haemorrhage (COPE): protocol for a phase IV, double-blind, double-dummy, randomised controlled trial and economic analysisCharlotte Van Netten, Kirtana Vallabhaneni, Ben Hardwick, et al.
British Journal of Clinical Pharmacology|May 13, 2026
ACKR1/Duffy-null genotype testing for clozapine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx)Stephen Murtough, Oriella Stellakis, Daisy Mills, et al.
Pageof 22